News coverage about T2 Biosystems (NASDAQ:TTOO) has trended somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. T2 Biosystems earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media stories about the medical equipment provider an impact score of 47.1099451353192 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- T2 Biosystems, Inc. (TTOO) stock recent close stands at $5.42 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Analysts’ Recommendation in Spotlight: T2 Biosystems, Inc. (NASDAQ: TTOO) – The Investor Guide (wallstreetnews24.com)
- Reviewing STAAR Surgical (STAA) & T2 Biosystems (TTOO) (americanbankingnews.com)
- T2 BIOSYSTEMS, INC. – StreetInsider.com (streetinsider.com)
- T2 Biosystems Inc (TTOO) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
A number of equities research analysts have recently issued reports on TTOO shares. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of T2 Biosystems in a research report on Friday, November 3rd. Zacks Investment Research upgraded shares of T2 Biosystems from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Wednesday, November 8th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $6.00 price target on shares of T2 Biosystems in a research report on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. T2 Biosystems presently has an average rating of “Hold” and a consensus price target of $6.54.
T2 Biosystems (NASDAQ:TTOO) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.04. T2 Biosystems had a negative net margin of 1,497.70% and a negative return on equity of 244.82%. The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $1.10 million. T2 Biosystems’s revenue was up 2.8% on a year-over-year basis. equities research analysts expect that T2 Biosystems will post -1.85 earnings per share for the current year.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.